A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q

Clinical trial NCT00885508 · UNKNOWN

Trial details

NCT number: NCT00885508
Sponsor: Groupe Francophone des Myelodysplasies
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia Acute Myeloid Leukemia

Start date: 2009-02-01
Primary completion: 2015-12-01
Enrollment: 85

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.